

CLAIMS

1. ~~A-Use of a composition~~ comprising at least one compound selected from synthetic polysulfated oligosaccharides having 1 to 4 monosaccharide units, salts and complexes thereof, ~~for use as in the manufacture of an agent for a wound cleaning agent treatment.~~

2. The ~~composition~~use as claimed in claim 1, characterized in that the aforementioned compound is selected from synthetic polysulfated oligosaccharides having 1 or 2 monosaccharide units preferably selected from pentoses and hexoses, as well as salts and complexes of these compounds.

3. The ~~composition~~use as claimed in claim 1 or 2, characterized in that the aforementioned compound is selected from:

- the potassium salt of sucrose octasulfate;
- the silver salt of sucrose octasulfate;
- sucralfate.

4. The ~~composition~~use as claimed in one of claims 1 to 3, characterized in that the aforementioned compound is combined with one or more other active substances for inducing or accelerating healing or that can have a favorable role in wound treatment.

5. The ~~composition~~use as claimed in claim 4, characterized in that the aforementioned active substance is selected from:

- bactericidal or bacteriostatic agents, such as in particular chlorhexidine, silver salts or complexes, zinc salts or copper salts, metronisazole, neomycin;
- local anesthetics, such as in particular lidocaine;
- anti-inflammatories, such as in particular nonsteroidal anti-inflammatories and cyclooxygenase-2 inhibitors;
- corticoids.

6. The ~~composition~~use as claimed in any one of claims 1 to 5, characterized in that the aforementioned compound is combined with one or more additional wound cleaning agents.

7. The ~~composition~~use as claimed in claim 6, characterized in that the aforementioned additional wound cleaning agent is selected from:

- enzymes; and
- urea.

8. ~~The composition~~use as claimed in any one of claims 1 to 7, characterized in that the aforementioned compound is used in a pharmaceutical formulation, ~~for example a gel, a solution, an emulsion, a cream, granules or capsules permitting application directly on the wound,~~ preferably in an amount between 0.1 and 50 wt.%, relative to the total weight of the formulation.

9. The use as claimed in any one of claims 1 to 8, characterized in that the aforementioned compound is used in a pharmaceutical formulation selected from the group consisting of: a gel, a solution, an emulsion, a cream, granules or capsules.

9~~10~~. ~~The composition~~use as claimed in any one of claims 1 to ~~89~~, characterized in that the aforementioned compound or a pharmaceutical formulation containing it is integrated with an element of a dressing, ~~preferably in an amount such that the amount of this compound released in wound exudates is between 0.001 g/l and 50 g/l, and more preferably between 0.001 and 10 g/l.~~

10~~11~~. ~~The composition~~use as claimed in claim 9~~10~~, characterized in that the aforementioned dressing is a dressing based on absorbent fibers.

11~~12~~. ~~The composition~~use as claimed in claim 9~~10~~, characterized in that the aforementioned dressing is a dressing comprising:

- a nonwoven consisting of superabsorbent fibers combined with thermal-bonding fibers whose surface coming in contact with the wound is covered with a discontinuous layer of adhesive.

12~~13~~. ~~The composition~~use as claimed in claim 11~~12~~, characterized in that the aforementioned adhesive is a hydrocolloid adhesive and in that the aforementioned polysulfated oligosaccharide is incorporated in said adhesive.

14. The use as claimed in claim 13, characterized in that the aforementioned polysulfated oligosaccharide is incorporated in said adhesive, preferably in an amount between 1 and 15 wt.-%, % relative to the weight of the adhesive.

15. The use as claimed in claim 13, characterized in that the aforementioned polysulfated oligosaccharide is incorporated in said adhesive ~~more preferably between~~ 5 and 10 wt.%, relative to the weight of the adhesive.